Background: Ambulatory Blood Pressure Monitoring (ABPM) may be helpful for the management of hypertension, but little is known about its tolerability in people with dementia.
and 0.11-0.32 for diastolic blood pressure). One study compared home BP monitoring by a relative or ambulatory BP monitoring with office BP measures, and found high agreement (κ 0.81). The little available evidence suggested increased levels of dementia being associated with reduced tolerability.
Conclusions: ABPM is well-tolerated in people with mild-moderate dementia, and provides some additional information over and above office BP alone. However, few studies have addressed ABPM in people with more severe dementia.
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Key points
 Essential hypertension and dementia commonly co-exist  People with dementia are particularly susceptible to the potential harms associated with over-treatment of hypertension  Ambulatory Blood Pressure Monitoring is a useful adjunct to office blood pressure monitoring, and is tolerated in people with dementia able to attend clinics  There is a paucity of data on the tolerability of blood pressure monitoring in people with more advanced dementia
Background
Hypertension is a global health challenge, with a prevalence of 50% in community dwelling people aged 65 years or older [1] . Out-of-office Blood Pressure (BP) is an important adjunct to conventional office or clinic measurement, which presently remains an important method for screening, diagnosing and managing hypertension [2] . Out-of-office BP monitoring includes 24-hour Ambulatory Blood Pressure Monitoring (ABPM), as well as home blood pressure monitoring (HBPM); both have the advantage of capturing a number of BP measurements in a more natural environment [2] . ABPM is therefore particularly useful in patients with anxiety, or potential haemodynamic side effects such as symptomatic hypotension, or where BP variability is expected or observed. The 2011 National Institute for Health and Clinical Excellence (NICE) guidelines suggested that the diagnosis and treatment decisions in hypertension should no longer be based on office measurements alone, and that confirmatory out-of-office measurements should be mandatory [1] .
Dementia represents another global health challenge, affecting 35.6 million people worldwide in 2010 [3] . The prevalence of hypertension in people with dementia ranges between 35%-84% [4] . ABPM is likely to be particularly useful in the management of hypertension in people with dementia, who commonly experience issues such as anxiety, haemodynamic side-effects and BP variability. However, for ABPM to be useful in widespread practice in people with dementia, it needs be tolerable and acceptable, and produce results that are complementary to office measures.
The most recent European guidelines do not advise on the management of hypertension in older people with dementia [2] . It appears that little is known about the tolerability of ABPM in people with dementia, so we undertook a review of the existing literature.
The aim of this systematic review was to determine the tolerability of home BP monitoring in older people with hypertension and dementia, defined as follows: A hand search of the references of extracted articles was also conducted to identify potential studies not captured in the electronic database searches.
Inclusion criteria
• Studies including people diagnosed with dementia • BP was measured using HBPM or ABPM One team member (MK) screened abstracts identified from the initial search. If a study met the initial selection criteria or its eligibility could not be determined from the title or abstract, the full text was retrieved. Two reviewers (MK and SC) then independently assessed the full text papers for inclusion eligibility; any discrepancies were resolved through discussion.
Included studies were graded using the Critical Appraisal Skills Programme (CASP) tool for observational studies by both reviewers [5] . A cut-off score of more than 50% for scored items was used for retaining papers, with disagreements again resolved through discussion.
Outcomes
The primary outcome of interest was the proportion of individuals with dementia who were able to tolerate ABPM (as defined according to the individual study criteria, or if not stated, then using the definition of tolerability from O'Brien et al [2003] [6] which requires a minimum of 14 readings during the day and seven readings at night).
Secondary outcomes included:
• Agreement between ABPM readings versus clinic BP in people with dementia • Any reasons why ABPM was not tolerated in people with dementia Data were extracted from the selected papers using a spreadsheet by both reviewers independently, and where this was not available, the original authors were contacted for further information. Considerable efforts were made to track down primary data including web searches to identify authors that had changed institution and personal contacts with co-authors or collaborators; if the authors were not contactable or the data not available, the study was excluded.
The PRISMA statement [7] was used to guide design and reporting.
Analysis
Data were abstracted from the original papers by two reviewers (MK, SC), and crosschecked for accuracy.
The proportion of people able to tolerate 24-hour ABPM was combined in a metaanalysis. Heterogeneity was quantified with the I 2 statistic, which measures the percentage of variation among studies due to heterogeneity rather than to chance. We considered heterogeneity to be important when I 2 was more than 30%. ranging from 9 to 23. All reported upon ABPM, with no studies reporting upon home BP monitoring. The overall quality of studies was good (mean CASP score 79%). The study selection process in shown in figure 1 and the summary data are shown in table 1. Full-text articles assessed for eligibility (n = 10)
Full-text articles not obtained because: (i) conference proceedings only (n=5) (ii) authors not contactable to determine eligibility (n = 5) (iii) duplicate publications (n=4)
Studies included for analysis (n = 5, see Table 1) Full-text articles excluded because of missing key outcomes n=5 For the primary outcome (the proportion of individuals with dementia who were able to tolerate ABPM), I 2 was 91% indicating significant heterogeneity, therefore the random effects estimate was used for the summary estimate. In a population with predominantly mild-moderate and some with severe dementia, ABPM tolerability was 77.7% (95% CI 62.2-93.2%) ( Figure 2 ).
Figure 2 Reported 24-hour ABPM tolerability for people with dementia
Only two studies reported agreement between office BP and home BP measurements (Kennelly, Mosselo); Pearson's correlation coefficients were moderate-weak for both Only one study (Nesti 2014 ) examined further the issues underpinning tolerability, noting that people with more severe dementia or higher levels of agitation measured using the Neuropsychiatric Index were less tolerant of ambulatory BP monitoring.
Discussion
The overall tolerability of ABPM monitoring in people with dementia was 77.7% (95% CI 62.2-93.2%) based on our meta-analysis of four studies, which is similar to other patient cohorts [19, 20] . The correlation between ABPM and office BP measurements was moderate to weak, but based on only two studies. Little was reported on the reasons why ABPM was not tolerated, but more advanced dementia appears to be associated with less tolerability. People with more severe cognitive impairment were significantly under-represented in these studies; most of the studies only included populations that were well enough to attend clinic settings, including the five excluded studies for who our primary outcome was not available.
The studies included were heterogeneous in terms of design (cohort studies and case control studies), but similar in that they reported on blood pressure measurement in people with dementia; the overall quality was high (minimum CASP score 68%). Despite efforts to contact authors of original studies to identify all possible data, we were unable to obtain data from studies involving older people with moderate to severe dementia.
The studies that were identified but not included in this review appeared similar in terms of the population studied, but it is possible that ABPM might be in use in those with moderate to severe dementia and only a limited amount of this experience has been studied and reported. This limits the generalisability of the findings to populations with more severe cognitive impairment.
The correlation between ABPM and office BP measurements was moderate to weak, in contrast to studies involving people without dementia, which find strong correlations of around 0.61 for systolic BP and 0.55 for diastolic BP [21] . Although this could be interpreted as demonstrating that ABPM is potentially inaccurate, a more likely interpretation is that there are important differences in ambulatory and clinic BP measures in people with dementia and hence that ABPM offers complementary information. However there were only two studies reporting on this and further studies would be required before making any clinical recommendations based on these data.
These findings provide some reassurance that, in a predominantly clinic-based population with dementia, ABPM will be feasible in the majority. This is helpful as older patients with cognitive dysfunction are at increased risk of white coat hypertension [22] , and so might be used to avoid unnecessary treatment in those people who do not have sustained hypertension. Additional advantages of ABPM include identification of periods of hypotension, which is associated with a range of adverse outcomes in people with dementia, including accelerated cognitive decline [23] [24] [25] [26] and falls [27] . ABPM can also identify orthostatic hypotension, which accompanies hypertension in around 30% of older people in general [28] , which is associated with vascular mortality [29] and allcause mortality [30] .
This review has not fully addressed the issue of assessing blood pressure in people with more advance dementia, who were under-represented in the studies to date, and arguably who are at greater risk of harm.
